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ABSTRACT
Motivation. Predominant pathway analysis approaches treat pathways as collections
of individual genes and consider all pathway members as equally informative. As
a result, at times spurious and misleading pathways are inappropriately identified
as statistically significant, solely due to components that they share with the more
relevant pathways.
Results. We introduce the concept of Pathway Gene-Pair Signatures (Pathway-
GPS) as pairs of genes that, as a combination, are specific to a single pathway. We
devised and implemented a novel approach to pathway analysis, Signature Over-
representation Analysis (SIGORA), which focuses on the statistically significant
enrichment of Pathway-GPS in a user-specified gene list of interest. In a comparative
evaluation of several published datasets, SIGORA outperformed traditional methods
by delivering biologically more plausible and relevant results.
Availability. An efficient implementation of SIGORA, as an R package with precom-
piled GPS data for several human and mouse pathway repositories is available for
download from http://sigora.googlecode.com/svn/.
Subjects Bioinformatics, Computational Biology, Molecular Biology, Immunology, Infectious
Diseases
Keywords Systems biology, Functional analysis, Over-representation analysis, Pathway analysis,
Shared components, High-throughput data
INTRODUCTION
Pathway analysis identifies biological pathways that are statistically enriched in a given
dataset and plays a crucial role in the interpretation of high-throughput experimental
datasets including gene or protein expression profiles (Khatri & Dra˘ghici, 2005; Huang,
Sherman & Lempicki, 2009) and genome-wide association studies (GWAS) (Wang, Li &
Hakonarson, 2010). Pathway analysis can guide the understanding of complex biological
datasets through the statistical association of observations at the molecular level to
processes at the systems level. Such analysis can, for example, highlight processes that
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Table 1 Annotation and co-annotation of human genes in current pathway repositories. The number of human genes annotated in pathways in
the KEGG, Reactome and PID databases. On average more than 40% of genes are annotated in more than one pathway whereas gene-pairs rarely
co-occur in multiple pathways.
Pathway
database
Number of
annotated genes
% of genes annotated
in a single pathway
% of genes annotated
in multiple pathways
Number of
co-annotated
gene-pairs
% of gene-pairs
that co-occur
in a single pathway
KEGG 5,660 48% 52% 1,205,807 90%
REACTOME 5,046 62% 38% 197,034 87%
PID BIOCARTA 1,368 54% 46% 32,361 78%
PID NCI 2,374 51% 49% 116,852 87%
are dysregulated in certain pathological conditions, such as cancer (Copeland & Jenkins,
2009) or infection (Wherry et al., 2007).
Currently, two types of pathway analysis methods are widely used: Over-representation
Analysis (ORA) methods (reviewed in Khatri & Dra˘ghici, 2005) and methods related
to Gene Set Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005;
Dinu et al., 2009).
Despite major differences between ORA and GSEA methods (see e.g., Emmert-Streib
& Glazko, 2011, for a discussion), these approaches share a notable limitation: most
current methods treat all genes in a given pathway as equal indicators that that pathway is
significant. This assumption, that each gene in a pathway has the same power to distinguish
one pathway from another, and that genes assume their roles without consideration of the
context and expression of other genes, is undoubtedly flawed (Gillis & Pavlidis, 2011; Ma,
Sartor & Jagadish, 2011; Khatri, Sirota & Butte, 2012).
To illustrate this point, consider four protein kinases, PRKACA, PRKACB, PRKACG,
and PRKX. Within the KEGG (Kanehisa et al., 2011) pathway repository, these genes are
members of 24 different pathways, i.e., they co-occur in roughly 10% of KEGG human
pathways (Fig. 1). Consider a dataset where all four of these genes were observed to be
differentially expressed — many pathway analysis tools would identify all 24 different
pathways as statistically significant leaving the biologist perplexed as to which of these
pathways are the most biologically relevant to their study. The underlying problem (that
genes may be associated with multiple pathways and, as such, that all genes are not
equivalent “Signatures” of a given pathway) is widespread and not limited to kinases.
Within KEGG, 52% of genes are annotated in more than one pathway (Table 1).
As a result, many pathway analysis methods return misleading statistically significant
pathways that are significant solely due to shared components with other pathways (e.g.,
“Prion Disease” is identified as a significant pathway in a dengue fever microarray study
(Hoang et al., 2010) simply because many of the genes annotated in this “pathway” are
co-annotated in inflammation-related pathways).
Here, we report a novel approach to address this problem, which involves the iden-
tification of statistically over-represented Pathway Gene-Pair Signatures (Pathway-GPS)
(i.e., weighted pairs of genes which uniquely occur together in a single pathway). The
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Figure 1 Not all genes have the same power to distinguish between different pathways. In this example,
all current KEGG annotations of seven selected genes are shown. Red: annotated in pathway; white: not
annotated in this pathway.
use of such gene pairs is also motivated by the data in Table 1: in contrast to single
genes, co-annotated gene pairs tend to be specific to a single pathway. We provide an
implementation of this approach in R (SIGORA; downloadable from http://sigora.
googlecode.com/svn/). We describe this approach and demonstrate how SIGORA
significantly reduces the identification of spurious pathways in analyses of simulated and
real biological datasets.
MATERIALS AND METHODS
Algorithm
As illustrated in Fig. 2, our approach to the problem consists of two phases: In an offline
phase, we compile a set of weighted markers/Signatures for each pathway in a repository,
which we call Pathway Gene-Pair Signatures (Pathway-GPS). Subsequently, in an online
phase, the method identifies the statistical over-representation of such Signatures in a
user-specified gene list using an adapted version of the hypergeometric test.
Given a pathway repository (e.g., KEGG), for each gene-pair in a pathway, SIGORA
investigates the co-appearance of the two genes in other pathways of the repository.
A gene-pair that uniquely occurs in a single pathway is considered a Signature of that
pathway and is assigned a weight. The weight of a Signature (from [0, 1]) quantifies
the average commitment of the components of the GPS towards the common pathway,
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Figure 2 SIGORA’s two phases. In the off-line phase (left) a pathway repository is transformed to disjoint
sets of weighted GPS. These precompiled signatures are used in the on-line phase (right) to evaluate a
user specific input gene list.
i.e., the weight scores the reliability of the Signature as evidence for the associated pathway.
For hierarchically organized repositories (like REACTOME (Matthews et al., 2009)),
this process is repeated iteratively after the removal of pathways on the top level of the
repository, i.e., in each iteration, new weighted Signatures are identified for the pathways
on the lower, more specific levels of the hierarchy. Once this offline stage is completed, the
resulting sets of weighted gene-pairs that represent each pathway are non-overlapping and
can be re-used for pathway analysis of any user-specified gene lists.
When presented with a gene list of interest (e.g., genes that are differentially expressed),
SIGORA determines which of the pairs from its (pre-compiled) Signature repository can
be reconstructed from the genes in the list. A Signature is considered “present” only if
both of its constituent genes are found in the user-specified query list. This inherently
leads to the selection of the more relevant roles of a gene in the experimental context, as
SIGORA relies on the status of the other genes in the pathway for the reconstruction of
the Signatures. For each pathway, the weights of present Signatures are summed up and
hypergeometric probabilities are used to assess the statistical significance of the observed
Signature sets.
Pathway Gene-Pair Signatures (Pathway-GPS)
A pathway database/repository contains (at least) two types of entities: pathways and genes.
This can be represented by a bipartite graph (or bipartite network) B = (Vg,Vp,E) with
two distinct sets of nodes (Vg: gene nodes and Vp: pathway nodes) where the edges in
E connect the genes to the pathways and signify the annotation of a gene in a particular
pathway (Fig. 3A). In this graph, the degrees (number of incident edges) of the pathway
nodes correspond to pathway sizes (i.e., the number of genes annotated in the pathway)
and the degree of the gene nodes corresponds to the number of different pathways a gene is
annotated in. In particular, genes with degree one are exclusively annotated within a single
pathway (‘Pathway Unique Genes (PUGs)’).
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Figure 3 Overview of the signature transformation. (A) A schematic pathway repository as a bipartite
graph (B); G1. . . G5: genes; P1. . . P3: pathways. (B) A pathway unique gene. (C) A Gene-Pair Signature
(GPS): G3 and G4 co-occur only in P2. (D) Each GPS is associated with a single pathway and has a weight
equal to the average inverse degree (in B) of its constituent genes.
Using the igraph (Csardi & Nepusz, 2006) package of the R-Statistical Framework
(R Development Core Team, 2008), B can be manipulated and transformed. A weighted
one-mode projection (Newman, 2001) of B into the gene dimension, yields a new graph
Proj = (Vg,E′,W)with only one type of nodes (only gene nodes Vg), where two genes are
connected by an edge in E′ if (and only if) they are co-annotated in one or more pathways,
and each edge is associated with a weight (in W) which signifies the number of pathways
that are shared between the two incident genes (i.e., the two genes connected by the edge).
Two genes connected by an edge of weight one in Proj are, as a combination, unique to a
single pathway. We call such pairs Pathway Gene-Pair Signatures (Pathway-GPS) of that
pathway. The process of identifying PUGs and Pathway-GPS for all pathways in a given
repository is termed the ‘Signature Transformation’ of the repository.
Hypothetically, one could go beyond gene-pairs and also consider n-tuples (with n> 2)
of genes that co-occur in a single pathway P as signatures of P. The possible benefits of
such extensions, however, do not currently seem to justify the associated complications to
the computational and methodological framework. This point is further discussed in the
Text S1.
Assignment of weights to GPS
As, by definition, each Pathway-GPS is uniquely associated with a single pathway,
identifying such Signatures in a gene list of interest (e.g., observing that both constituent
genes of a Pathway-GPS are in the list of differentially expressed genes) can serve as an
indicator of the activation/perturbation of the associated pathway. Each pathway can
(and usually does) have multiple possible Pathway-GPS, and (as discussed below) the
method does not rely on the observation of an individual GPS but rather on the statistical
over-representation of multiple GPS in comparison to the expected proportion.
Yet before the over-representation of GPS can be used for the identification of relevant
pathways, we need to emphasize that different GPS vary in their reliability as indicators
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of a particular pathway. This is due to the fact that, while the two genes comprising
a Pathway-GPS can only be co-annotated in a single pathway, each of the two genes
– considered individually – can be a member of several distinct pathways.
Consider GPS of the form (g1,g2) for a pathway P, where g1 is annotated in i pathways
and g2 is in j pathways. Intuitively, a GPS that consists of two PUGs (i.e., a case where
i = j = 1) is a more appealing signature than a GPS that consists of two ‘multifunctional’
genes (say, i= 4 and j = 3), where the simultaneous observation of the two genes might be
due to other factors (e.g., simultaneous activation of two different pathways).
To address this issue, a weight is assigned to each GPS to quantify its reliability as an
indicator of its associated pathway. Let (g1, g2) be a GPS associated with a pathway P and
let i and j be the number of individual pathways annotations of g1 and g2, respectively. The
weight of the GPS is
wi,j = 1
2
(
1
i
+ 1
j
)
= i+ j
2 ∗ i ∗ j .
A motivation for this weighting scheme and a discussion of alternative weighting strategies
can be found in the Text S1. In the implementation, the user also has access to several
alternative weighting schemes and user defined schemes are also supported. Figure 3
summarizes the main ideas behind the compilation of weighted Signatures for a given
pathway repository.
Identifying statistically over-represented Pathway-GPS
Analogous to traditional (individual gene) ORA (IG-ORA) methods, the distribution
function of hypergeometric probabilities is used to calculate p-values indicating the
statistical enrichment of Pathway-GPS in a user-specified gene list, which is given by:
p(k,n,m,N)= p(x ≥ k)= 1−
k−1∑
x=0
(
m
x
)(
N −m
n− x
)
(
N
n
) .
In individual gene ORA, k denotes the number of query genes in the tested pathway, n the
number of the genes in the pathway, N the number of all (assayed or annotated) genes,
and m the length of the query list (i.e., the number of the genes with interesting status). In
contrast to these traditional approaches, however, the parameters of the hypergeometric
function in SIGORA are calculated as sums of GPS weights rather than frequency statistics
of individual gene annotations. The Signature ORA parameters for p-value calculations are
summarized in Table 2.
Note that – strictly speaking – hypergeometric probabilities are only defined on natural
numbers while the sums of GPS weights are positive floating point values, which is why
the table refers to rounded values of the sums (to the closest integer). Theoretically, this
rounding could lead to a ‘blurring of the weights for pathways with few GPS’, however, in
practice this issue hardly materializes, as such pathways are very rare (e.g., 219 out of 226
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Table 2 Interpretation of the hypergeometric distribution test parameters used in SIGORA. A GPS is
present if both of its component genes are in the query list.
Parameter Interpretation in SIGORA
k (success) Rounded sum of the weights of all present GPS of the tested pathway
n (success states) Rounded sum of the weights of all possible GPS of the tested pathway
N (universe) Rounded sum of the weights of all possible GPS of the repository
m (sample size) Rounded sum of the weights of all present GPS
KEGG human pathways in our repository are associated with 10 or more possible GPS). In
tests with simulated and real biological data sets, different choices of the rounding strategy
(floor, ceiling or nearest integer) did not substantially affect the significance or the rank
order of the identified pathways. As an aside, in the widely popular statistical framework
R, the phyper function (which computes the distribution function of the hypergeometric
distribution) does accept non-integer (floating point) parameters and handles such input
by applying the following rounding strategy: the number of successes is rounded down, all
remaining parameters are rounded to the closest integer value.
In our implementation, the user has the option to restrict the GPS-sets for the
universe (N), and the success states (n) by providing a list of assayed genes (background).
Furthermore, all PUGs are by default considered to represent a GPS of weight 1 (as a
combination of the PUG with itself), but the user has the option to restrict the analysis to
pairs of genuinely distinct genes.
Multiple testing correction
Undertaking pathway analysis generally involves a large numbers of significance tests.
As testing a multitude of hypotheses will inevitably lead to some ‘significant’ results,
adjustment of p-values for multiple testing is a crucial feature of any pathway analysis
tool. Bonferroni’s method is used by default in SIGORA for multiple testing correction
(MTC). It is, however, relatively easy to change the MTC procedure, if a user prefers to
explore other adjustment methods (see the implementation section).
Selection of cut-off threshold for statistical significance of
pathways
The choice of a reasonable cut-off threshold for statistical significance of the hypergeomet-
ric test results is an open methodological question in IG-ORA. In practice, values smaller
than 0.1 or 0.05 after correction for multiple testing are commonly considered significant.
Shifting the perspective from individual genes to the weighted Gene-Pair Signatures brings
an additional challenge: as the size of the universe for the hypergeometric test dramatically
increases (we move from a few thousand genes to up to a few hundred thousand weighted
gene-pairs), the calculated p-values become by several orders of magnitude smaller than
those observed in a typical IG-ORA analysis.
Based on our experience with simulated and biological datasets, we recommend a
significance threshold of 0.001 after MTC (by Bonferroni). In the implementation, the
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default output of the analysis is the ranked list of pathways that achieve a corrected p-value
up to this value. The user can also export the entire results table (including the p-values,
corrected p-values and the parameters of the hypergeometric test) and the evidence (lists of
present PUGs, list of the genes involved in present GPS or list of all present GPS along with
their weights).
Dealing with redundancies of semantic origin
Thus far, we have described the motivation for Signature Transformation from a biological
perspective. However, in some cases, there are additional semantic reasons for sharing
of components among pathways. In particular, some repositories (e.g., REACTOME
(Matthews et al., 2009), INOH (Yamamoto et al., 2011) and Gene Ontology (Ashburner
et al., 2000)) are organized in a hierarchical structure, where all genes associated with one
pathway (child) are also included in a more general pathway (parent). This poses a general
challenge for pathway analysis tools that ideally should identify the most relevant level
of the hierarchy (Alexa, Rahnenfu¨hrer & Lengauer, 2006; Grossmann et al., 2007; Jupiter,
Sahutoglu & VanBuren, 2009).
The hierarchical nature of such repositories poses a special challenge for our method. As
any gene-pairs from a child category also co-occur in the parent pathway, they would thus
be excluded from being identified as a possible Signature. This would have the undesirable
effect that all child pathways on the lower levels of the hierarchy would be left without any
Signatures at all in the offline stage and hence be undetectable by SIGORA in the online
stage.
To address this issue, we deploy the following iterative top-down strategy in the offline
stage (Signature Transformation):
1. Set level = 1. Compile the repository Signatures as described for the non-hierarchical
case. Assign the compiled signatures to level 1.
2. Remove all pathways from the top level of the hierarchy, increase the level and recompile
Signatures for the remaining pathways. Assign the GPS to the current level. Iterate this
step until no further hierarchical levels can be removed.
Figure S1 illustrates this procedure on a simplified hierarchical repository. In the online
stage (the identification of significantly over-represented Signatures in a user-specified gene
list) the user can specify how many levels of the hierarchy should be considered in the anal-
ysis. Any GPS (and any pathways) that are deeper down the hierarchy (i.e., are at a higher
threshold level) are left out of the universe (and the analysis). If the user (for instance) asks
for analysis up to the second level, then only GPS from levels one and two are considered.
The effect of this simple modification (i.e., the iterative strategy for Signature Transfor-
mation) is similar to a combination of the Elim (Alexa, Rahnenfu¨hrer & Lengauer, 2006),
and TreeHugger (Jupiter, Sahutoglu & VanBuren, 2009) algorithms in dealing with GO’s
structure. Elim essentially excludes genes in more specific categories from consideration in
more general categories, whereas TreeHugger weakens the contribution of such genes to the
higher levels.
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 8/27
Complexity and computational cost of the method
The complexity of the transformation step (in an implementation based on the outlined
bipartite network interpretation of gene-pathway membership) is dominated by the
complexity of the bipartite projection, which is given as:
O(‖V‖ ∗ d2+‖E‖)
With ‖V‖: number of nodes in the network (number of genes+ number of pathways), d
the average degree of nodes, ‖E‖ the number of edges in the bipartite network.
For most inputs, the online phase (i.e., analysis of user specific input lists using the
precompiled Signatures) completes within 15 s on a standard laptop (1.8 GHZ, 2 GB of
RAM).
Implementation
SIGORA is implemented as an R package. The package and a detailed manual are available
for download from http://sigora.googlecode.com/svn/. The following highlights the most
important steps in a typical work-follow in R (requires R version≥2.10):
## install and load the downloaded package
>install.packages(‘sigora 0.9.8.tar.gz’, type=‘source’, repos = NULL)
>library(‘sigora’)
## (please note that all of the following commands require that the package is already loaded)
## import the query list from a file (assuming the list is given as Ensembl gene IDs):
>myquerylist<-ens converter(scan(‘myfile.txt’,what=‘character’))
## Alternatively, if the file consists of Entrez gene IDs
>myquerylist<-entrez converter(scan(‘myfile.txt’))
## perform signature over-representation analysis, using KEGG GPS
>sigs(myquerylist,‘k’,markers=1,level=2)
## multiple testing correction is done by Bonferroni and FDRs are also provided.
In order to add Hommel’s method:
>cbind(summary results,p.adjust(summary results[,5],‘hommel’))
## export the results into a file
>export results(filename=‘my results.csv’, genes=T)
## help (on Windows systems, help is shown in the web-browser)
>help(sigs)
## the following demo is also available
>demo(sigora)
Evaluation methods
We evaluated the performance of SIGORA by comparison to several other analysis tools on
simulated and published biological datasets. Three of the methods compared are based on
individual gene over-representation (DAVID (Huang, Sherman & Lempicki, 2009; Jiao et al.,
2012), gProfileR (Reimand et al., 2007), InnateDB (Lynn et al., 2008)) and the remaining
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three (GSEA Preranked, GSEA (Subramanian et al., 2005), GSEA AF (Ma, Sartor &
Jagadish, 2011)) are GSEA based. Acknowledging the inherent challenges associated with
comparison of p-values across different statistical frameworks, for each tool we follow the
recommendations of the authors of that tool regarding the choice of the most appropriate
significance threshold and multiple testing correction (MTC) method (Text S1).
Among the methods listed above, we use DAVID, gProfileR, GSEA PRERANKED for
the simulation study, as these tools (like SIGORA) can be run on any pre-selected gene list
and in ‘batch mode’. GSEA and Appearance frequency modulated GSEA (AF) are limited
to particular experimental designs and have specific input data format requirements,
and are used here only in the analysis of three biological dataset for which data in the
required input format was available. InnateDB is used as a reference point in evaluation
of the biological datasets, because SIGORA’s GPS are based on pathway annotation data
as present in InnateDB. The rationale for selecting GSEA is its popularity; while AF was
chosen because it attempts to address similar issues as SIGORA.
A short summary of the relevant characteristics of each of these methods is given below.
InnateDB (www.innatedb.com (Lynn et al., 2008; Breuer et al., 2013))
InnateDB’s pathway analysis interface provides traditional IG-ORA using the standard hy-
pergeometric test. Its recommended MTC method is Benjamini–Hochberg. The pathway
GPS in SIGORA’s current implementation are calculated using the pathway annotation
as present in the latest release of InnateDB. In other words, any observed differences in
analysis results between SIGORA and InnateDB are solely due to the differences between
Signature-over-representation and individual-gene over-representation, and there are no
additional confounding issues regarding the gene identifier mapping or different update
status of the repositories across tools. We compare InnateDB to SIGORA using three
biological datasets.
gProfileR (http://biit.cs.ut.ee/gprofiler/(Reimand et al., 2007))
gProfileR is the R package associated with the web-server of same name. Like InnateDB, it
deploys a traditional individual gene over-representation based method using the standard
hypergeometric test. In gProfileR, p-values are corrected by default using a unique multiple
testing correction method (MTC), called the Set Counts and Sizes (SCS) procedure, which
is analytically derived from extensive simulation experiments and purports to account
for “the actual structure behind functional annotations”. In other words, issues relating
to the overlapping structures within annotation repositories are believed to be addressed
indirectly and implicitly, as a special case of MTC. We use gProfileR in the simulation
experiment. For completeness, we also list gProfileR’s results on the three biological
datasets evaluated here; however, some of the pathways listed by gProfileR are very recent
additions to the KEGG repository that are as yet not available in other tools, including our
current implementation of SIGORA.
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DAVID (http://david.abcc.ncifcrf.gov/(Huang, Sherman & Lempicki, 2009;
Jiao et al., 2012))
DAVID provides individual-gene pathway analysis over-representation analysis using the
EASE Score, a modified Fisher Exact p-value that is designed to raise the bar for statistical
significance of smaller pathways. This avoids situations in which observation of only a
few genes from a small pathway would make it equally (or even more) significant than
observing dozens of genes from a larger pathways. The EASE Score is generally more
conservative than the Fisher Exact p-values.
Apart from this modification, DAVID’s functional annotation charts implement a
traditional individual gene over-representation based method that treats all genes
equally. DAVID has also introduced the concept of functional annotations clusters that
are motivated by the idea that rather than focusing on significance of individual pathways,
the true nature of a phenotype should be examined by considering the overall emerging
picture of interrelated pathways. In some situations, clusters of interrelated pathways can
be considered collectively significant while some (or most) of the individual pathways
in those clusters might fall slightly beyond the significance threshold. Although this
is undoubtedly a sensible statement, the measure of interrelatedness used in DAVID’s
functional clusters is in diametrical contrast to the reasoning behind SIGORA: DAVID’s
authors postulate that similar pathways tend to contain similar gene members. In DAVID’s
functional annotation charts, the more common genes annotations share, the higher
chance they will be grouped together as interrelated pathways, and the better the chances of
the emerging cluster to become (collectively) significant.
For the simulation experiment, we will focus on DAVID’s functional charts. In our
evaluation of analysis results on biological datasets, we will also briefly exemplify the
pitfalls of DAVID’s Functional clusters.
GSEA (Subramanian et al., 2005)
The three methods discussed above (InnateDB, gProfileR and DAVID) are over-
representation based methods that (like SIGORA) operate on a pre-filtered list of genes of
interest (query list). The list of genes of interest is often determined using a (combination
of) threshold(s) (e.g., fold change and p-value of differential expression). The p-values are
in essence derived from a contingency table.
GSEA, in contrast, is the most prominent representative of a very different category of
pathway analysis tools that do not operate on a pre-selected list and do not use contingency
tables. In GSEA, all genes in the dataset are first ranked by their difference regarding a
single biological metric (e.g., signal to noise ratio) between the two conditions. This ranked
gene list is then used to assign a normalized enrichment score (NES) – defined as the
maximum deviation of a running sum statistic from zero, adjusted for the number of genes
in the pathway – to each pathway. The statistical significance of the NES is determined by
sample permutation (i.e., randomly exchanging the phenotype class labels).
We compare GSEA and SIGORA in the analysis of three biological datasets. Some of
the observed differences in the results of GSEA analysis to SIGORA are inevitably due to
the fundamental differences between ORA and GSEA methods. In particular, regardless
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of their biological relevance to the examined dataset (or lack thereof), the significance
of some of pathways observed by GSEA is due to ‘subtle but coordinated changes’ in
expression levels of genes that are not in the list of differentially expressed genes.
This issue equally applies to the two remaining methods, GSEA-PRERANKED and AF,
which are described below.
GSEA-PRERANKED
As the name suggests, this is a variant of GSEA where the input format is not an expression
matrix, but a pre-ranked list of genes. Accordingly, as there is no sample information
available, the statistical significance is derived from gene set permutation instead of sample
permutations. Technically, applying GSEA and GSEA-PRERANKED to the same dataset
can lead to identical NES, but very different FDRs (http://www.broadinstitute.org/gsea/
doc/GSEAUserGuideFrame.html). Hence, the recommended threshold for statistical
significance is different (0.05 instead of 0.25). We compare GSEA-PRERANKED to
SIGORA in analysis of simulation datasets. Like standard GSEA, GSEA-PRERANKED
does not provide a mechanism for dealing with shared components of pathways.
Appearance Frequency modulated GSEA (AF) (Ma, Sartor & Jagadish,
2011)
AF is a recently proposed variant of GSEA that is explicitly designed to deal with issues
posed by shared components. In this respect (the intended benefit), AF is the most
similar method to SIGORA among all methods compared here. AF assigns weights to
individual genes based on number of associated pathways and performs a GSEA analysis.
Methodologically, AF inherits most of GSEA’s characteristics and is quite distinct from
SIGORA. We compare AF and SIGORA in the analysis of three biological datasets.
Simulation experiment
Creation of simulated input lists
As a preliminary measure to quantify the effect of shared components on the number of
spurious pathways, we conducted a simulation experiment over 1,000s of simulated gene
lists that are created by applying the following procedure: From a set of 175 human KEGG
human pathways that are in the repository of all four compared tools (SIGORA, DAVID,
gProfiler and GSEA preranked), n pathways are chosen at random and a fraction (alpha) of
genes in each selected pathway are marked as differentially expressed (DE). The restriction
to 175 common pathways is intended to reduce the effects of diverging update-status across
analysis tools. The list of DE genes from five selected pathways is used as a query list for
SIGORA, gProfiler and DAVID. To create an input list for GSEA preranked, a score of 2
is assigned to the selected DE genes and a score of 1 to all remaining human genes. This
procedure is repeated 1,000 times at fixed values for alpha and n.
Biological datasets
We further compare each of the different pathway analysis tools by examining their results
when applied to three different gene expression datasets. These datasets incorporate
the results of microarray studies investigating the host response to a parasite infection
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(Experimental Cerebral Malaria), a viral infection (Dengue Fever), and a bacterial
infection (Tuberculosis) (Lovegrove et al., 2007; Thuong et al., 2008; Hoang et al., 2010).
We map the lists of differentially expressed genes in each experiment (as provided by the
authors of the respective studies) to unique Ensembl/Entrez IDs and use the resulting sets
as input lists for four over-representation based methods (InnateDB, DAVID, gProfiler
and SIGORA), ensuring that all methods are run on identical input lists. Additionally, two
GSEA-based methods (GSEA and AF) are also applied to the corresponding expression
datasets obtained from the gene expression omnibus (GEO): GSE25001, GSE11199,
GSE11199.
RESULTS
Results on simulated gene lists
To evaluate the performance of SIGORA, we compared it to three other popular pathway
analysis methods (DAVID, gProfiler and GSEA Preranked) applied to simulated data,
where we know a priori which are the significant pathways. The simulated input data was
created by randomly choosing five KEGG pathways and selecting a fraction (alpha, 50% or
15%) of the genes in each of these pathways as being “differentially expressed”. Each of the
methods was then applied to the selected gene list to determine the statistically significant
pathways (using the respective recommended significance threshold and MTC approach,
see Text S1).
If the sharing of genes between different pathways was not a factor, we would expect that
each method should identify only the five preselected pathways as significant. As can be
seen in Table 3, in our experiments (using 1,000 simulated datasets with alpha= 50% and
1,000 datasets with alpha= 15%), this was not the case: gProfileR, for example, identified
more than 60 pathways on average as being significant at alpha = 50%, despite only 5
pathways being simulated as significant in the input data. SIGORA performed best by this
measure and identified on average 8 pathways as significant across the different datasets.
The Recall and Precision metrics in the third and fourth columns of Table 3 capture the
relationship between originally preselected ‘target’ pathways and the identified pathways.
More specifically: Recall describes the fraction of the target pathways that were identified as
significant and Precision signifies the fraction of statistically significant pathways that were
among the originally selected pathways. Neither of these two metrics by itself is decisive,
and there is a certain trade-off between the two metrics. This trade-off is captured by the
F1-score, the harmonic mean of Precision and Recall. As can be seen in Table 3, SIGORA
had the best F1 scores when compared to the other methods.
Finally, note that although this analysis is based on recommended significance thresh-
olds in each method, Precision, Recall and F1 score are all dependent on the – ultimately
arbitrary – choices of significance thresholds. The last column in Table 3 describes the
results according to a less threshold-dependent measure. Ideally, the preselected pathways
would occupy the first five positions in the list of the identified pathways, resulting in an
average rank of 3. As can be seen in the last column of Table 4, at both choices for alpha
(15% or 50% of the genes in each pathway selected) the average rank of the originally
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Table 3 Performance metrics for several pathway analysis methods run on 1,000 simulated gene lists at two different alphas (15% or 50%). Each
of the simulated datasets contained either 15 or 50% of genes in 5 randomly chosen pathways. For each analysis method and each input gene
list, the identified (statistically significant) pathways were recorded and the Precision (true positive results/all significant pathways), Recall (true
positive/chosen) and F1 score (harmonic mean of Precision and Recall) were calculated by comparing the list of the (n) chosen pathways with the list of
identified pathways. More specifically, for the purpose of this analysis, a statistically significant pathway is considered a true positive if it is among the
five chosen pathways and a false positive otherwise; furthermore, any chosen pathways that are not identified by a method as statistically significant
are considered false negatives. The entries in bold show the method with the best performance according to each measure.
Alpha Method Average number
of significant
pathways
Average
Recall
Average
Precision
F1 score (harmonic
mean of Precision
and Recall)
Average rank of the
original pathways within
the analysis results
DAVID 11.22 0.71 0.32 0.44 6.8
gProfiler 34.17 0.95 0.14 0.24 7.8
GSEA Preranked 0.09 0.01 0.74 0.03 29.6
15%
SIGORA 6.41 0.72 0.56 0.63 3.6
DAVID 30.25 0.98 0.16 0.28 6.8
gProfiler 62.48 0.99 0.08 0.15 8
GSEA Preranked 13.91 0.87 0.32 0.46 5.6
50%
SIGORA 8.87 0.89 0.50 0.64 3.7
preselected pathways (‘target pathways’) in SIGORA’s results (3.6 and 3.8 respectively) is
very close to this ideal value, whereas the other methods tend to identify several additional
pathways as more significant than the target pathways, resulting in higher average ranks of
target pathways in these methods.
Results on published datasets
In addition to the simulated data, we also compared SIGORA to five different methods
(InnateDB, DAVID, gProfileR, GSEA and AF) applied to real biological data, in this
case three different gene expression datasets. Full details of the input genes, p-values and
highlighted pathways obtained by each method can be found in the Tables S1–S3.
Tuberculosis
SIGORA was compared to five different pathway analysis methods (InnateDB, DAVID,
gProfileR, GSEA and AF) applied to a gene expression dataset (GSE11199) which measured
the host transcriptional response in human macrophages infected with Mycobacterium
tuberculosis (Thuong et al., 2008). 1,250 transcripts (corresponding to 1,100 distinct
Ensembl genes) were identified by Thuong et al. as being induced in response to this
infection. Figure 4 shows the pathways that were identified as statistically significant by
each of the six methods. The first thing that one notes is that the GSEA-based methods
tended to predict large numbers of pathways as statistically significant (the AF method
predicted nearly a third of the KEGG database as significant in this example). This is
somewhat by design, as GSEA methods attempt to identify subtle but coordinated changes
in gene expression. This may be very helpful in investigating cases where there are only
subtle differences between conditions but in a dataset like this one, it leaves the biologist
bewildered as to which pathways should be followed-up on experimentally. In the other
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Table 4 List of all pathways identified as statistically significant by each method compared in this
study and their respective ranks (by p-value) in the analysis of a Dengue fever gene expression
dataset. The entries in bold are significant largely due to sharing genes with other more relevant
pathways.
DAVID GSEA AF gProfileR InnateDB SIGORA
Systemic lupus erythematosus 1 3 2 1 1
Hepatitis C 10 2
Complement and coagulation cascades 2 3 3 3
RIG-I-like receptor signaling pathway 1 3 9 4
Cytosolic DNA-sensing pathway 2 1 4 5
Osteoclast differentiation 7 6
Chemokine signaling pathway 6 7
Lysosome 8
Antigen processing and presentation 9 9
NOD-like receptor signaling pathway 4 4 10
Toll-like receptor signaling pathway 6 8 5 11
Staphylococcus aureus infection 2
Long term potentiation 10
Leishmania infection 5 11
Ribosome 5
Malaria 6
Allograft rejection 7
Prion diseases 12 8
Measles 1
Influenza A 2
Herpes simplex infection 4
Pertussis 5
extreme is DAVID, which predicted only 4 pathways as statistically significant. SIGORA,
on the other hand, identified 12 pathways as statistically significant; 10 of which were also
identified by at least two other methods. Comparing the pathways identified by SIGORA as
significant to the significant pathways identified by the other methods, one can see (Fig. 5)
that many of the pathways identified by other methods as significant but not by SIGORA
share many genes with the SIGORA pathways. Notably, after removing the multifunctional
genes that are involved in the pathways identified by SIGORA from the input list, the
individual gene over-representation based methods (DAVID, InnateDB and gProfileR)
did not return any significant pathways at all. This reinforces our observation from the
simulated data that SIGORA will identify truly significant pathways but avoid identifying
pathways that are significant because they share genes with other more relevant pathways.
Interestingly, SIGORA may also be able to identify some important pathways that are
not significant using other methods. One pathway was identified as significant in this
dataset only by SIGORA; FcγR-mediated phagocytosis. Fcγ receptors regulate immune
activation and susceptibility during Mycobacterium tuberculosis infection (Maglione et al.,
2008; Maertzdorf et al., 2011) and it has been implied that “entry through Fcγ receptors
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Figure 4 (continued on next page...)
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Figure 4 (...continued)
Results of six different pathway analysis methods applied to a gene expression dataset measuring the
host transcriptional response toM. tuberculosis infection of human macrophages. The heatmap shows
all pathways that were identified as statistically significant by at least one of the six different pathway
analysis methods. The more red the color the higher the rank of that pathway for a particular method.
The heatmap is sorted by the number of methods identifying a particular pathway as significant.
may specify a distinct intracellular trafficking pathway for virulent M. tuberculosis” (Ernst,
1998). Finally, DAVID’s top functional cluster for this dataset (Enrichment score 0.99)
contained 16 pathways, 12 of which are different cancer subtypes (Table S1).
Table S1 lists all Pathways identified as statistically significant by each of the considered
methods and their respective ranks (by p-value) in analysis of this dataset.
Experimental cerebral malaria
Example 2 is a mouse cerebral malaria (ECM) dataset, comparing the whole-brain
transcriptional responses of genetically susceptible (C57BL/6) and resistant (BALB/c)
inbred mouse strains 6 days after infection with Plasmodium berghei ANKA (NCBI GEO:
GSE7814) (Lovegrove et al., 2007). We fist performed a differential expression analysis using
Geo2R to obtain a list of up-regulated genes at FDR<0.01 (637 Ensembl genes, Table S2).
We use this list as input for SIGORA, InnateDB, gProfileR and DAVID, and apply GSEA
and AF to the corresponding expression matrix.
Similar to the previous example, the number of KEGG pathways that different methods
identified as statistically significantly enriched in this dataset varied widely: AF identified
59 pathways (out of 185 in its repository), while DAVID highlighted just two pathways.
SIGORA identified 14 pathways as significant, 13 of which were also reported by at least
two other methods (Fig. 6, Table S2). The remaining pathway is PPAR signaling pathway
(discussed further below).
Aside from this big-picture view, the strong changes in the rank orders of the following
individual pathways are also worth mentioning:
Complement and coagulation cascades
This pathway is the 6th ranked pathway in SIGORA’s results. Three additional tools
(InnateDB, GSEA and AF) also identify this pathway as significant, but only at considerably
lower ranks (the 17th, 25th and 27th position, respectively). Complement and coagulation
pathways have been shown to be critically involved in the development of ECM (Van der
Heyde et al., 2006; Francischetti, Seydel & Monteiro, 2008; Ramos et al., 2012).
Leukocyte transendothelial migration
This pathway is the 7th ranked pathway in SIGORA’s results, the 23rd ranked pathway in
GSEA and the 44th ranked pathway in AF. The remaining methods do not identify this
pathway as statistically significant. Polymorphonuclear leukocyte recruitment has been
shown to be responsible for increased permeability of the blood–brain-barrier, and is
strongly associated with fatality rates in ECM (Senaldi et al., 1994; Bell, Taub & Perry, 1996).
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Figure 5 Number of differentially expressed genes that are shared between SIGORA’s pathways (ver-
tical axis, ordered by rank) and additional pathways identified as significant by other methods on the
TB dataset.
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Figure 6 Comparison of results of six different methods on a mouse experimental cerebral malaria
dataset. The heatmap shows all pathways that were identified as statistically significant in at least one of
five different pathway analysis methods. The more red the color the higher the rank of that pathway for a
particular method. The heatmap is sorted by the number of methods identifying a particular pathway as
significant.
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PPAR signaling pathway
This pathway is at position 14 of SIGORA’s results. The only other method to identify
PPAR signaling is AF, at position 47. Targeting of PPAR is currently being explored as
a novel adjunctive therapy for cerebral malaria (Balachandar & Katyal, 2011; Serghides,
2012). Notably, PPARγ has been reported to be one of only two genes in a cerebral
malaria-resistance locus identified using a genome-wide analysis of 32 different inbred
mouse lines (Bopp et al., 2010) and modulation of the inflammatory response to P. berghi
infection by an antagonist of this gene has greatly enhanced the survival rates in mice
(Serghides et al., 2009).
At the same time, SIGORA avoids a few biologically implausible pathways that are
considered highly significant by at least two other methods: e.g., “Staphylococcus aureus
infection” (a bacterial infection) is the most significant pathway in InnateDB’s results, and
the second highest ranked pathway in gProfileR’s results, but is not significant in SIGORA’s
results. Similarly, GSEA and AF both identify “Prion diseases” as significant (position 2
and 4, respectively) and again, this pathway is not significant in SIGORA’s results. Other
examples include: “Small cell lung cancer” (GSEA, AF), “Viral myocarditis” (InnateDB,
gProfileR, AF), “Type I diabetes mellitus” (InnateDB, gProfileR) (Fig. 6 and Table S2).
DAVID’s top ranking functional cluster for this dataset (Enrichment Score: 2.7)
groups “Antigen processing and presentation”, “Viral myocarditis”, “Allograft rejection”,
“Graft-versus-host disease”, “Type I diabetes mellitus” and “Autoimmune thyroid disease”
together (Table S2). All of these pathways having highly overlapping annotations.
Dengue fever
As a third evaluation set, we re-examined a list of 483 up-regulated genes in the whole
blood transcriptome of patients infected with dengue virus (NCBI GEO: GSE25001)
(Hoang et al., 2010). More specifically, we compared expression profiles of hospitalized
patients with uncomplicated Dengue during acute phase (≤72 h of illness history) to
follow up samples of such subjects two weeks after discharge (n= 72).
Here, for the most part, the SIGORA results contain well-defined immunity related
pathways. As before, some additional, potentially spurious pathways that are identified
by other methods are not significant in the SIGORA analysis. Examples include
“Staphylococcus aureus infection” (the second ranked pathway in InnateDB results) and
the “Prion Disease” pathway (identified by both InnateDB and AF). These two pathways
share components with the complement pathway (4 and 6 up-regulated genes respectively,
Fig. 7), which has been shown to have a role in neutralising Dengue (Shresta, 2012).
Again, this example contains a possibly relevant pathway that was significant in
SIGORA’s results, but overlooked by the other methods: “Lysosome”, at position eight
of SIGORA’s results (Table 4, Table S3). Recent experimental evidence suggests that
manipulation of the host’s autophagolysosomes by the dengue virus is an important part of
the virus’s life cycle (Khakpoor et al., 2009; Heaton & Randall, 2010).
DAVID does not return any functional clusters for this dataset.
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Figure 7 Number of differentially expressed genes that are shared between SIGORA’s pathways (rows,
ordered by rank) and additional pathways by other methods (columns) in the analysis of the Dengue
dataset.
Discussion and related work
The existence of shared components between pathways poses a challenge for pathway
analysis methods: which of the statistically significant pathways associated with such
components are the most biologically significant? In 2005, Khatri and Dra˘ghici surveyed
the state of the art analysis methods and tools of the time and outlined several limitations
as the challenges for the next generation of analysis tools. One such challenge “is related
to genes that are involved in several biological processes. For such genes, all current tools
weight all the biological processes equally. At the moment, it is not possible to single out the
more relevant one by using the context of other genes [of interest] in the current experiment”
(Khatri & Dra˘ghici, 2005).
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The years since have seen many interesting developments in the functional analysis of
high throughput biological data: Several methods (Alexa, Rahnenfu¨hrer & Lengauer, 2006;
Grossmann et al., 2007; Jupiter, Sahutoglu & VanBuren, 2009) have been described to high-
light processes at the appropriate level of specificity and to reduce the redundancy of the re-
sults in the context of Gene Ontology (GO) analysis, where the overlap between categories
are often due to the hierarchical organization of the ontology. These methods, however,
fail to account for overlap between pathways that don’t involve the full inclusion of all
members of a pathway in another pathway. To deal with such cases, Antonov et al. (2008)
proposed the creation of new functional categories as complex Boolean combinations of
available GO terms. Unfortunately, such combinations are often not easy to interpret and a
comprehensive search over all possible combinations is computationally infeasible.
Outside of GO, a few methods have been proposed that indirectly tackle the issue by
either discriminative treatment of individual genes or alternative representation of the
pathway repository in specific scenarios. An example of the later approach (alternative
representation of the pathway repository) is Bayesian Pathway Analysis, BPA (Isci et al.,
2011). BPA transforms each pathway in a pathway repository into a separate Bayesian
Network (BN) and scores the fit of each model with the experimental (expression) data.
BPA is expected to leverage the expression status of other genes in the experimental
context, as BNs, in contrast to simple lists of genes, are deemed capable of accommodating
local interactions between genes. Although highly sophisticated, BPA is computationally
intensive and by design limited to the interpretation of expression datasets.
An early example of the former approach (non-egalitarian treatment of individual
genes) is impact-analysis (Draghici et al., 2007). Impact analysis integrates the magnitude
of each gene’s expression change along with the type (e.g., receptor, transcription factor)
and position of each gene within the given pathways and their interactions into the
statistical framework, however, the authors do not explicitly address the problems related
to component sharing among pathways.
More recently, it has been proposed to add an appearance frequency based parameter
to the statistical framework of GSEA. This additional parameter is intended to weaken the
contribution of genes with multiple pathway memberships to the statistical significance
of all of their associated pathways (Ma, Sartor & Jagadish, 2011). While this is a significant
step in the right direction, the addition of such a parameter does not exploit the status
of other genes in the experiment for the selection of the most relevant function of
a gene in the experimental context. As exemplified by the gene, BRCA1 in Khatri &
Dra˘ghici (2005), even key players of one process (maintaining genomic stability) can
have several less prominent roles in other unrelated pathways (response to nutrient and
brain development). Nor can appearance frequency distinguish between the causes of
appearance of a gene in several pathways, which, aside from functional pleiotropy of
genes, can be partly due to the hierarchical organization of some pathway repositories like
REACTOME and GO.
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Here we introduced the concept of Pathway-GPS, as genes or gene-pairs that (as
a combination) are specific to a single pathway, and we described Signature Over-
representation Analysis (SIGORA) as a novel (and comparably efficient) approach to
pathway analysis. SIGORA uses Pathway-GPS to bridge the gap between the context
sensitive and collaborative nature of biological processes on one side and the universal and
discrete statistical framework of over-representation analysis on the other side. Although
each Signature’s weight is fixed in advance, the net contribution of an individual gene G to
the measured success (parameter k in Table 1) of each of its associated pathways is not fixed
and depends explicitly on the status of its partners (genes that together with G form a GPS).
In contrast to the GSEA-based solutions, SIGORA inherits the versatility of the ORA
statistical framework and is applicable to lists of genes of interest obtained in any type of
high throughput experimental set-up (e.g., copy number variations from cellular profiling,
lists of epigenetically silenced genes from promoter methylation analysis, differential gene
expression data from NGS and microarrays or SNPs from GWAS experiments) without the
need for adaptation of the computational method. This is especially notable in situations
where ranking of the entire dataset by a single biological parameter (as required by GSEA)
is not feasible (see Huang, Sherman & Lempicki, 2009, for a few examples).
CONCLUSIONS
This paper highlights the level of component sharing between pathways and demonstrates
how this can lead to misleading/spurious results in current pathway analysis approaches
that treat all pathway members as equally informative. Here we introduce a novel approach
that accounts for the overlapping structure of pathway annotation by focusing on unique
features (‘Signatures’) of pathways. To our knowledge, this is the first over-representation
based method to do so.
Applied to several published datasets, our approach highlights biologically meaningful
processes that would otherwise fall below statistical significance thresholds, and avoids
some of the biologically implausible processes highlighted by other methods. This suggests
that our approach delivers a useful complementary tool for pathway analysis.
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